Cosmo Pharmaceuticals N.V.
CMOPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,057,340 | $767,129 | $1,056,904 | $1,073,050 |
| - Cash | $44,296 | $50,275 | $185,825 | $198,560 |
| + Debt | $2,201 | $1,839 | $173,598 | $169,917 |
| Enterprise Value | $1,015,245 | $718,693 | $1,044,677 | $1,044,407 |
| Revenue | $266,788 | $92,780 | $102,089 | $65,074 |
| % Growth | 187.5% | -9.1% | 56.9% | – |
| Gross Profit | $246,923 | $53,440 | $83,327 | $49,934 |
| % Margin | 92.6% | 57.6% | 81.6% | 76.7% |
| EBITDA | $165,705 | $19,699 | $46,744 | $17,811 |
| % Margin | 62.1% | 21.2% | 45.8% | 27.4% |
| Net Income | $133,236 | -$4,932 | $17,225 | $21,672 |
| % Margin | 49.9% | -5.3% | 16.9% | 33.3% |
| EPS Diluted | 8.12 | -0.31 | 1.05 | 1.28 |
| % Growth | 2,719.4% | -129.5% | -18% | – |
| Operating Cash Flow | $162,411 | $22,708 | $33,226 | $12,611 |
| Capital Expenditures | -$5,653 | -$4,396 | -$7,310 | -$8,504 |
| Free Cash Flow | $156,758 | $18,312 | $25,916 | $4,107 |